Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17728341 | 0.99 | ESR1 (0.40) | ESR1GRIN1GRIN2BMAPTL3MBTL1 | |
| SCHEMBL10169847 | 0.89 | ESR1 (0.43) | ESR1GRIN1GRIN2BMAPTESR2 | |
| Hydrochloric Acid SCHEMBL9957448 | 0.88 | ESR1 (0.43) | ESR1GRIN1GRIN2BMAPTESR2 | |
| SCHEMBL10169845 | 0.87 | ESR1 (0.44) | ESR1GRIN1GRIN2BMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL9956555 | 0.86 | ESR1 (0.43) | ESR1GRIN1GRIN2BMAPTL3MBTL1 | |
| SCHEMBL10169693 | 0.85 | ESR1 (0.43) | ESR1GRIN1GRIN2BMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL9956790 | 0.85 | ESR1 (0.43) | ESR1GRIN1GRIN2BMAPTL3MBTL1 | |
| SCHEMBL10169844 | 0.84 | ESR1 (0.41) | ESR1GRIN1GRIN2BESR2 | |
| SCHEMBL10169843 | 0.84 | ESR1 (0.42) | ESR1GRIN1GRIN2BESR2 | |
| SCHEMBL10169723 | 0.84 | ESR1 (0.42) | ESR1GRIN1GRIN2BMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | ESR1 2/4885GRIN1 2150/4885GRIN2B 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.